Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

Formulary 2-5

Our regular review of pharmacotherapy

Our regular review of pharmacotherapy Emergent Therapies New antidiabetic shows promise in patients with renal disease  Data from a new phase 3 study has demonstrated that once-daily liraglutide (Victoza) provided greater glycaemic control versus placebo with no worsening of renal function in adults who have type 2 diabetes coupled with moderate renal impairment (stage 3 chronic kidney disease).   Renal impairment is one of the more common and challenging long-term complications of diabetes and limits the use of available antidiabetic treatment options. In the UK, the risk of developing chronic kidney disease stages 3b-5 among people with diabetes is around eight

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy